[go: up one dir, main page]

MX2020013217A - Metodos para generar celulas madre hematopoyeticas. - Google Patents

Metodos para generar celulas madre hematopoyeticas.

Info

Publication number
MX2020013217A
MX2020013217A MX2020013217A MX2020013217A MX2020013217A MX 2020013217 A MX2020013217 A MX 2020013217A MX 2020013217 A MX2020013217 A MX 2020013217A MX 2020013217 A MX2020013217 A MX 2020013217A MX 2020013217 A MX2020013217 A MX 2020013217A
Authority
MX
Mexico
Prior art keywords
hematopoietic stem
stem cells
endothelial
methods
cells
Prior art date
Application number
MX2020013217A
Other languages
English (en)
Inventor
Dhvanit I Shah
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of MX2020013217A publication Critical patent/MX2020013217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En algunos aspectos y modalidades, la invención proporciona métodos para producir células madre hematopoyéticas, incluyendo para el HSCT. El método comprende proporcionar una población celular que comprende células endoteliales hemogénicas (HE) o endoteliales, y aumentar la actividad o expresión de ADN (citosina-5-)-metiltransferasa 3 beta (Dnmt3b) y/o Miembro 6 de la familia GTPasa IMAP (Gimap6) en las células HE y/o endoteliales en condiciones suficientes para estimular la formación de las HSC.
MX2020013217A 2018-06-07 2019-06-07 Metodos para generar celulas madre hematopoyeticas. MX2020013217A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681982P 2018-06-07 2018-06-07
PCT/US2019/035949 WO2019236943A2 (en) 2018-06-07 2019-06-07 Methods for generating hematopoietic stem cells

Publications (1)

Publication Number Publication Date
MX2020013217A true MX2020013217A (es) 2021-05-12

Family

ID=68770737

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013217A MX2020013217A (es) 2018-06-07 2019-06-07 Metodos para generar celulas madre hematopoyeticas.
MX2025006880A MX2025006880A (es) 2018-06-07 2020-12-04 Metodos para generar celulas madre hematopoyeticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025006880A MX2025006880A (es) 2018-06-07 2020-12-04 Metodos para generar celulas madre hematopoyeticas

Country Status (12)

Country Link
US (4) US12286643B2 (es)
EP (1) EP3802790A4 (es)
JP (1) JP7599953B2 (es)
KR (1) KR20210018437A (es)
CN (1) CN112585261A (es)
AU (1) AU2019282761B2 (es)
BR (1) BR112020024979A2 (es)
CA (1) CA3103133A1 (es)
IL (1) IL279172A (es)
MX (2) MX2020013217A (es)
SG (1) SG11202011962TA (es)
WO (1) WO2019236943A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210018437A (ko) 2018-06-07 2021-02-17 더 브리검 앤드 우먼즈 하스피털, 인크. 조혈 줄기 세포를 생산하기 위한 방법
CA3164120A1 (en) * 2019-12-09 2021-06-17 The Brigham And Women's Hospital, Inc. Methods for generating hematopoietic stem cells
CN115551881A (zh) * 2020-04-30 2022-12-30 北京生命科学研究所 毛囊干细胞丢失的药物靶点及应用
AU2021396389A1 (en) * 2020-12-10 2023-07-27 Garuda Therapeutics, Inc. Methods for generating hematopoietic stem cells and compositions thereof
IL307219A (en) * 2021-03-31 2023-11-01 Garuda Therapeutics Inc Pluripotent stem cell-derived hematopoietic lineages
JP2025533905A (ja) * 2022-10-05 2025-10-09 ガルーダ セラピューティクス， インコーポレイテッド 修飾造血幹細胞及びその子孫
CN117305241B (zh) * 2023-11-28 2024-03-19 上海兴瑞一达生物科技有限公司 一种hiPSCs诱导分化为NK细胞的方法
WO2025217462A1 (en) 2024-04-10 2025-10-16 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease- specific populations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219869A1 (en) 1997-10-31 1999-04-30 Hsc Research And Development Limited Partnership Human cd-34 hematopoietic stem cells
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US20120195862A1 (en) * 2009-04-17 2012-08-02 Children's Medical Center Corporation Biomechanical induction of hematopoiesis
DK2816112T3 (en) 2009-12-10 2018-11-19 Univ Minnesota TAL effector-mediated DNA modification
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9540612B2 (en) 2012-01-30 2017-01-10 Icahn School Of Medicine At Mount Sinai Methods for programming differentiated cells into hematopoietic stem cells
CN113528577B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
ITMI20130067U1 (it) 2013-02-25 2014-08-26 Sunjade Invest Ltd Impianto per la produzione di energia elettrica
AU2014236285A1 (en) * 2013-03-14 2015-11-05 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
WO2016201133A2 (en) 2015-06-09 2016-12-15 The Regents Of The University Of California Hematopoietic cells and methods of using and generating the same
EP3307887A1 (en) * 2015-06-09 2018-04-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
CN108601356B (zh) 2015-12-03 2023-01-10 布里格姆妇女医院 生成功能性造血干细胞的方法
US11261430B2 (en) 2016-05-03 2022-03-01 The Children's Medical Center Corporation Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells
KR20210018437A (ko) 2018-06-07 2021-02-17 더 브리검 앤드 우먼즈 하스피털, 인크. 조혈 줄기 세포를 생산하기 위한 방법
CA3164120A1 (en) 2019-12-09 2021-06-17 The Brigham And Women's Hospital, Inc. Methods for generating hematopoietic stem cells

Also Published As

Publication number Publication date
US11597913B2 (en) 2023-03-07
JP7599953B2 (ja) 2024-12-16
EP3802790A4 (en) 2022-03-23
AU2019282761B2 (en) 2024-01-04
US20210222125A1 (en) 2021-07-22
WO2019236943A3 (en) 2020-01-09
EP3802790A2 (en) 2021-04-14
US20220290104A1 (en) 2022-09-15
US12286643B2 (en) 2025-04-29
SG11202011962TA (en) 2020-12-30
KR20210018437A (ko) 2021-02-17
US20260015583A1 (en) 2026-01-15
CA3103133A1 (en) 2019-12-12
AU2019282761A1 (en) 2021-01-07
MX2025006880A (es) 2025-07-01
CN112585261A (zh) 2021-03-30
US20230212517A1 (en) 2023-07-06
JP2021527397A (ja) 2021-10-14
BR112020024979A2 (pt) 2021-04-20
IL279172A (en) 2021-01-31
WO2019236943A2 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MX2025006880A (es) Metodos para generar celulas madre hematopoyeticas
CY1125251T1 (el) Ελεγχομενη μεταγραφη
MX2020008494A (es) Nanomateriales de silicio-carbono, metodo de su elaboracion y usos.
CL2021001034A1 (es) Métodos y composiciones para terapia con células oculares
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
CY1122940T1 (el) Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο προγραμματισμενου κυτταρικου θανατου 1
CL2020000345A1 (es) Mezclas agrícolas.
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
MX2021005013A (es) Métodos para la selección y estimulación de células y aparatos para los mismos.
MX2020008763A (es) Composiciones y metodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
BR112018067438A2 (pt) biomantas de fungos filamentosos, métodos para sua produção e métodos para seu uso
CL2018003510A1 (es) Anticuerpos antagonistas que se unen en forma de t a tgfb1, tgfb2 y tgfb3 humano, y su uso en el tratamiento de fibrosis pulmonar.
AR093045A2 (es) Un metodo de aplicar un herbicida a una planta transgenica para producir una semilla hibrida no natural transgenica, celulas no naturales y adn recombinante
BR112017010490A2 (pt) roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
MX366369B (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
CO2021018034A2 (es) Oligonucleótidos gapmer modificados y métodos de uso
MX2021008772A (es) Composiciones y metodos para la estimulacion de celulas natural killer.
BR112021008738A2 (pt) Processo para produzir células t geneticamente construídas
BR112022004562A2 (pt) Método de seleção de doador universal para identificar doadores de células nk
MX2017007214A (es) Procedimiento para la expansion de linfocitos t gamma/delta.
BR112022011169A2 (pt) Métodos para geração de células-tronco hematopoiéticas
MX2021000421A (es) Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer.
MX2024001443A (es) Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.